Clinical Trial Update: A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

View source ↗

Summary

The trial reports safety and effectiveness data for NovoThirteen (recombinant Factor XIII, rFXIII) in treating congenital Factor XIII deficiency in Japanese pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Xiii Deficiency

Drugs mentioned

• NovoThirteen (recombinant factor XIII (rFXIII))

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Status: COMPLETED